- Aimedbio's 'P001' has been selected as a "study on the establishment of novel therapeutics R&D ecosystem" project by the Korean Drug Development Project (KDDF). It will receive research funds to derive its candidate over the next two years.
- P001 is an immune antibody that targets upper receptors that suppress inflammatory reactions and treats allergic diseases caused by excessive inflammatory reactions.
- P001 is being developed with atopic dermatitis and chronic sinusitis as its main indicators, but Aimedbio is also considering various allergic diseases and autoimmune diseases as areas of indication expansion.
Link to full news: http://www.biospectator.com/view/news_view.php?varAtcId=19399